Literature DB >> 23439018

Imaging heart failure: current and future applications.

Ian Paterson1, Lisa M Mielniczuk, Eileen O'Meara, Aaron So, James A White.   

Abstract

A variety of cardiac imaging tests are used to help manage patients with heart failure (HF). This article reviews current and future HF applications for the major noninvasive imaging modalities: transthoracic echocardiography (TTE), single-photon emission computed tomography (SPECT), positron emission tomography (PET), cardiovascular magnetic resonance (CMR), and computed tomography (CT). TTE is the primary imaging test used in the evaluation of patients with HF, given its widespread availability and reliability in assessing cardiac structure and function. Recent developments in myocardial strain, 3-dimensional TTE, and echo contrast appear to offer superior diagnostic and prognostic information. SPECT imaging is a common method employed to detect ischemia and viability in patients with HF; however, PET offers higher diagnostic accuracy for both. Ongoing study of sympathetic and molecular imaging techniques may enable early disease detection, better risk stratification, and ultimately targeted treatment interventions. CMR provides high-quality information on cardiac structure and function and allows the characterization of myocardial tissue. Myocardial late gadolinium enhancement allows the determination of HF etiology and may predict patient outcomes and treatment response. Cardiac CT has become a reliable means for detecting coronary artery disease, and recent advances have enabled concurrent myocardial function, perfusion, and scar analyses. Overall, available imaging methods provide reliable measures of cardiac performance in HF, and recent advances will allow detection of subclinical disease. More data are needed demonstrating the specific clinical value of imaging methods and particularly subclinical disease detection in large-scale, clinical settings.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23439018     DOI: 10.1016/j.cjca.2013.01.006

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  11 in total

Review 1.  SPECT and PET in ischemic heart failure.

Authors:  George Angelidis; Gregory Giamouzis; Georgios Karagiannis; Javed Butler; Ioannis Tsougos; Varvara Valotassiou; George Giannakoulas; Nikolaos Dimakopoulos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis; Panagiotis Georgoulias
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

2.  Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: Development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT.

Authors:  Ian P Clements; Ernest V Garcia; Ji Chen; Russell D Folks; Javed Butler; Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2015-03-19       Impact factor: 5.952

3.  Patient satisfaction with coronary CT angiography, myocardial CT perfusion, myocardial perfusion MRI, SPECT myocardial perfusion imaging and conventional coronary angiography.

Authors:  S Feger; M Rief; E Zimmermann; F Richter; R Roehle; M Dewey; E Schönenberger
Journal:  Eur Radiol       Date:  2015-03-13       Impact factor: 5.315

4.  Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.

Authors:  Vaia Lambadiari; George Pavlidis; Foteini Kousathana; Maria Varoudi; Dimitrios Vlastos; Eirini Maratou; Dimitrios Georgiou; Ioanna Andreadou; John Parissis; Helen Triantafyllidi; John Lekakis; Efstathios Iliodromitis; George Dimitriadis; Ignatios Ikonomidis
Journal:  Cardiovasc Diabetol       Date:  2018-01-08       Impact factor: 9.951

Review 5.  Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction.

Authors:  Prathap Kanagala; Iain B Squire; Leong L Ng; Gerry P McCann
Journal:  Int J Cardiol Heart Vasc       Date:  2015-07-30

6.  New cardiac magnetic resonance imaging modalities aid in the detection of myocardial fibrosis.

Authors:  Katherine M Holzem
Journal:  Physiol Rep       Date:  2017-03

7.  Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging.

Authors:  Richard B Thompson; Kelvin Chow; Joseph J Pagano; Viktor Sekowski; Evangelos D Michelakis; Wayne Tymchak; Mark J Haykowsky; Justin A Ezekowitz; Gavin Y Oudit; Jason R B Dyck; Padma Kaul; Anamaria Savu; D Ian Paterson
Journal:  J Cardiovasc Magn Reson       Date:  2019-09-12       Impact factor: 5.364

8.  Effects of Choice of Medical Imaging Modalities on a Non-invasive Diagnostic and Monitoring Computational Framework for Patients With Complex Valvular, Vascular, and Ventricular Diseases Who Undergo Transcatheter Aortic Valve Replacement.

Authors:  Melissa Baiocchi; Shirley Barsoum; Seyedvahid Khodaei; Jose M de la Torre Hernandez; Sydney E Valentino; Emily C Dunford; Maureen J MacDonald; Zahra Keshavarz-Motamed
Journal:  Front Bioeng Biotechnol       Date:  2021-07-08

Review 9.  Heart Failure: Diagnosis, Management and Utilization.

Authors:  Arati A Inamdar; Ajinkya C Inamdar
Journal:  J Clin Med       Date:  2016-06-29       Impact factor: 4.241

10.  Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis.

Authors:  Max-Paul Winter; Patrick Sulzgruber; Lorenz Koller; Philipp Bartko; Georg Goliasch; Alexander Niessner
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.